Pfizer India Site Slammed By FDA
Warning Letter Criticizes Sterility Testing And Environmental Monitoring
Executive Summary
Pfizer's third US FDA warning letter since 2018 goes to injectables site in Vizag, India; tells the company to up its game in sterility testing and in the microbiology lab.